Science

Sidra Naz: ICI timing is an important consideration in cancer treatment

Sidra Naz/LinkedIn

Feb 8, 2025, 07:37

Sidra Naz: ICI timing is an important consideration in cancer treatment

Sidra Naz, Post-Doctoral Research Fellow at Harvard Medical School, shared an article by Malek Shatila, et al. on LinkedIn:

“Delighted to share that our manuscript has been published in Springer Journal Targeted Oncology!

Contributing to advancing precision medicine and improving patient outcomes in cancer treatment. Grateful to our Mentor Deputy Division of Head and collaborators for their dedication and support.

Key points:

Immune checkpoint inhibitors (ICIs) and stem cell transplantation (SCT) are two treatment modalities that have been offered for hematological malignancies and come with the risk of inflammatory adverse events.
No study to date has adequately explored the interplay between ICIs and SCT as well as the impact of ICI timing in relation to SCT in patients receiving both.
Our study found that patients who received ICIs prior to SCT had a higher risk of inflammatory adverse reactions compared with those receiving them after, suggesting that ICI timing is an important consideration in management of these patients.”

Checkpoint Inhibition Prior to Stem Cell Transplantation Increases the Risk of Inflammatory Adverse Events.

Authors: Malek Shatila, et al.

Sidra Naz: ICI timing is an important consideration in cancer treatment

cancer cancer treatment fight against cancer Global fight against cancer Harvard Medical School ICI Immune Checkpoint Inhibitors Malek Shatila OncoDaily Oncology SCT Sidra Naz Springer Journal

Stanley Tucci and Throat Cancer: How He Went Against, How He Survived, and More

Senator John Fetterman Responds to Oncodaily on Pediatric Oncology Funding

Does Processed Meat Cause Cancer? Myths and Facts

Global Health Dialogues with Princess Dina Mired | Episode 1: Dr. Firas Al-Hawari

NEW PAPER ALERT: ESOPEC trial on Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer